Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin⦠read more
Healthcare
Drug ManufacturersāSpecialty & Generic
25 years
USD
Exclusive to Premium users
$1.02
Price-2.86%
-$0.03
$34.858m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$97.727m
-
1y CAGR-
3y CAGR-
5y CAGR-$264k
-
1y CAGR-
3y CAGR-
5y CAGR-$0.01
-
1y CAGR-
3y CAGR-
5y CAGR$31.522m
$53.961m
Assets$22.439m
Liabilities$12.868m
Debt23.9%
5.5x
Debt to EBITDA$2.223m
-
1y CAGR-
3y CAGR-
5y CAGR